---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-22-117891"
form_type: "8-K"
ticker: "IMNM"
cik: "0001472012"
company_name: "Immunome Inc."
filed_at: "2022-11-14T23:59:59+00:00"
generated_at: "2026-06-21T19:55:13.532192+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Immunome reports Q3 net loss of $8.5M; cash $27.1M; COVID antibody trial on track

## Summary
- Net loss for Q3 2022 was $8.5 million; no revenue from product sales.
- R&D expenses $5.2M, G&A $3.3M; cash and equivalents $27.1M as of Sept 30.
- IMM-BCP-01 Phase 1b enrollment expected by end of 2022; topline data early 2023.
- Oncology pipeline advancing; IND for IMM-ONC-01 planned by mid-2023.
- Preclinical data on anti-EPN1 antibody IMM20059 at SITC showed combo effect with atezolizumab.

## SEC filing metadata
- accession: 0001104659-22-117891
- form_type: 8-K
- ticker: IMNM
- cik: 0001472012
- company_name: Immunome Inc.
- filed_at: 2022-11-14T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1472012/000110465922117891/0001104659-22-117891-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1472012/000110465922117891/tm2230173d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-22-117891
- JSON: https://secwatch.observer/filing/0001104659-22-117891.json
- Plain text: https://secwatch.observer/filing/0001104659-22-117891.txt

## Key facts
- Earnings Releases
  Immunome Inc. reported third quarter ended September 30, 2022 results: net income $8.5 million.
  - Period: third quarter ended September 30, 2022
  - Net income: $8.5 million
  - Result: reported results
  source text: Net loss: Net loss for the three months ended 2022 was $8.5 million.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1472012/000110465922117891/0001104659-22-117891-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.